Smallpox Vaccine for Mpox Post-Exposure Prophylaxis: A Cluster RCT
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
Mpox is a global disease. Post-exposure prophylaxis with smallpox vaccine has the potential
to prevent secondary cases and reduce symptom severity but it has not been proven in a trial
to be effective.
In this trial, we will randomly select households (as clusters), where each member living
with someone diagnosed with monkeypox will receive either the Bavarian Nordic smallpox
vaccine or the Typhoid vaccine as post-exposure prophylaxis. We will then see how many people
who received the smallpox vaccine versus the typhoid vaccine develop RT-PCR confirmed mpox,
and assess symptom severity in these households.